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Abstract Parkinson’s disease (PD) is a common neurodegen-
erative disorder affecting mostly elderly people, although
there is a group of patients developing so-called early-onset
PD (EOPD). Mutations in the PARK2 gene are a common
cause of autosomal recessive EOPD. PARK2 belongs to the
family of extremely large human genes which are often local-
ised in genomic common fragile sites (CFSs) and exhibit gross
instability. PARK2 is located in the centre of FRA6E, the third
most mutation-susceptible CFS of the human genome. The
gene encompasses a region of 1.3 Mbp and, among its muta-
tions, large rearrangements of single or multiple exons ac-
count for around 50 %. We performed an analysis of the
PARK2 gene in a group of 344 PD patients with EOPD and
classical form of the disease. Copy number changes were first
identified using multiplex ligation probe amplification
(MLPA), with their ranges characterised by array comparative
genomic hybridisation (aCGH). Exact breakpoints were
mapped using direct sequencing. Rearrangements were found
in eight subjects, including five deletions and three
duplications. Rearrangements were mostly non-recurrent and
no repetitive sequences or extended homologies were identi-
fied in the regions flanking breakpoint junctions. However, in
most cases, 1–3 bp microhomologies were present, strongly
suggesting that microhomology-mediated mechanisms, spe-
cifically non-homologous end joining (NHEJ) and fork
stalling and template switching (FoSTeS)/microhomology-
mediated break-induced replication (MMBIR), are predomi-
nantly involved in the rearrangement processes in this geno-
mic region.
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Introduction
Parkinson’s disease (PD) (MIM 168600) is the second most
common neurodegenerative disorder, of which around 10 %
of cases have genetic underpinnings (Thomas and Beal 2007).
Early-onset PD (EOPD) is a form of the disease when the first
symptoms appear before the age of 45 years. Additionally,
juvenile PD (PDJ) is a subdivision of EOPD where the first
symptoms appear at 30 years of age or even earlier (Schrag
et al. 1998; Friedman 1994). The list of genetic factors
causing or increasing the risk of PD has been constantly
growing over the last 15 years. However, mutations of three
genes, PARK2 (MIM 602544), PINK1 (MIM 608309) and
DJ-1 (MIM 602533), are responsible for the majority of
EOPD cases following autosomal recessive (AR) pattern
of inheritance (Bonifati 2014). PARK2 gene mutations are
particularly common among AR-EOPD patients and the
vast majority of PDJ patients are diagnosed with mutations
in this gene (Kitada et al. 1998; Lücking et al. 2000). To
date, over 200 different PARK2 mutations have been
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identified, half of which are point mutations and the other half
large gene rearrangements. However, it is still unknown if all
the identified genetic changes are pathogenic (Hedrich et al.
2004). The PARK2 gene is located on chromosome 6, locus
6q25.2-q27 and encompasses a genomic region of 1.3 Mbp.
The gene consists of 12 exons and its 4.5 kbp transcript con-
tains a 1,395 bp open reading frame (NCBI 2012). PARK2
belongs to the family of extremely large human genes and is
located within FRA6E, one of the most unstable common
fragile sites (CFSs) of the human genome (Smith et al. 2006).
CFSs are intrinsically difficult to replicate genomic regions
prone to forming chromosomal breakages (Glover 1998;
Sutherland et al. 1998). They are highly conserved and con-
stitute a normal part of chromosomes, although the level of
their expression is variable among individuals (Denison et al.
2003a). CFSs are stable in cultured cells, but form gross mu-
tations when exposed to replication stress. Replication inhib-
itors like aphidicolin, bromodeoxyuridine (BrdU) and 5-
azacytidine have been used to induce the expression of CFSs
(Durkin and Glover 2007).
CFSs are known to play a major role in carcinogenesis
(Smith et al. 2006). They are hotspots for gene amplifications
(Coquelle et al. 1997), viral integration (Popescu and DiPaolo
1989) and are also preferentially involved in sister–chromatid
exchange (Glover and Stein 1987). It has been reported that the
majority of the largest human genes form part of CFSs (Smith
et al. 2006). Little is known about direct mechanisms underly-
ing the susceptibility to breakages and rearrangements of CFSs.
Nevertheless, some factors have been considered to contribute
to instabilities, including late-replicating genomic regions, high
AT content, flexible DNA sequences or regions enriched in
repetitive elements (Wells and Ashizawa 2006;Ma et al. 2012).
FRA6E is one of 16 CFSs to have been characterised to
date at the molecular level (Lukusa and Fryns 2008) and the
third most mutation-susceptible of them (Denison et al.
2003b). In cultured cells, its instability can be induced by
aphidicolin. The exact size of the region of instability of this
CFS is not yet clear; however, it has been suggested that it
may span even 9 Mb at 6q25.1-6q26 (Russo et al. 2006).
Although FRA6E contains many genes, its main fragility core
is localised on the telomeric end, within the PARK2 gene se-
quence (Denison et al. 2003b; Palumbo et al. 2010). The mu-
tational hotspot spans the region between exons 2 and 8 of the
gene (Denison et al. 2003c).
In order to investigate why CFSs are susceptible to rear-
rangements, it is necessary to shed light on the clustering and
sequence features of breakpoint regions. Among a cohort of
Polish PD patients, we identified eight cases of PARK2 gene
rearrangements (deletions and duplications). Their
breakpoints have been identified and characterised. Subse-
quently, we attempted to pinpoint which molecular mecha-
nism is predominantly involved in rearrangement formation
in the FRA6E locus.
Materials and methods
Subjects
Analysis was performed using the DNA of 344 patients with
EOPD and idiopathic, late-onset form of PD (LOPD) who
entered the study on the molecular background of PD in pa-
tients of Polish origin. The group consisted of 171 EOPD and
173 LOPD patients. Males were a small majority in both of
them (EOPD, n=97, 57.30 %; LOPD, n=99, 57.65 %). The
age of onset in the entire group varied between 12 and 88
years, among EOPD patients 12 and 45 years [mean 36.8;
standard deviation (SD)±6.98] and among LOPD patients
46 and 88 years (mean 58.33; SD±9.79). At the time of ex-
amination, the mean patient age was 55.83 years (SD±13.37);
in the EOPD and LOPD groups, respectively, it was 45.53
years (SD±8.35) and 66.07 years (SD±8.76). All patients
were assessed by a neurologist and neurological examinations
were performed by clinicians experienced in the diagnostic of
movement disorders (partial clinical data already published by
Koziorowski et al. 2010, 2013; Hoffman-Zacharska et al.
2013). Clinical diagnosis of PD patients was established ac-
cording to the UK Parkinson’s Disease Brain Bank criteria
(Hughes et al. 2001).
Genomic DNA samples of all subjects came from the
DNA bank of the Department of Molecular Genetics, In-
stitute of Mother and Child in Warsaw, Poland. DNA of
the subjects from the control group belonged to healthy
individuals, with no family history of any neurological
diseases. All the DNA samples were previously screened
for point mutations in all 12 exons of PARK2 using Sang-
er sequencing.
All participants signed an informed consent.
The ethic committees of Warsaw Medical University and
the Institute of Mother and Child approved the study.
DNA screening
In order to detect large PARK2 rearrangements, we employed
the multiplex ligation probe amplification (MLPA) technique
using commercially available SALSA P051-C1 and P052-C1
Parkinson MLPA kits (MRC-Holland). Both probe sets con-
tain probes specific for all the PARK2 exons, as well as select-
ed exons of other genes associated with different PD forms
(http://www.mrc-holland.com). MLPA experiments were
performed according to the manufacturer’s instructions. The
probes were hybridised for 14 h and 100 ng of DNAwas used.
Reaction products were separated with an ABI 3130 Genetic
Analyzer (Applied Biosystems). GeneMarker v1.51 software
(SoftGenetics LLC) was used for dosage ratio analysis
(standard parameters, dosage ratio boundaries <0.75 and >1.
25 for deletions and duplications, respectively).
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Rearrangement analysis
To confirm the presence of identified deletions/duplications
and to define more precisely the range of rearranged regions,
array comparative genomic hybridisation (aCGH) was per-
formed using the NimbleGen 385K chromosome 6 tiling array
with 349 bp median probe spacing (NimbleGen, Roche). Ar-
rays were scanned on an Agilent G2565CAMicroarray Scan-
ner System (Agilent) and images were analysed using DEVA
v1.0.2 software (NimbleGen, Roche). Genomic positions of
the rearrangements were specified according to the Human
Mar.2006 (NCBI36/hg18) assembly (UCSC Genome Brows-
er, http://genome.ucsc.edu).
Breakpoint mapping
Based on the coordinates of aCGH probes, for each of the
patients, we designed primer pairs using Primer3 software
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi).
The specificity of oligonucleotides was validated with in-
silico polymerase chain reaction (PCR) (UCSC Genome
Browser). In order to map the exact breakpoints, we per-
formed PCR reactions using the FastStart High Fidelity PCR
System (Roche). PCR products were directly sequenced on
both strands with primers used for PCR amplification. Se-
quencing reactions were performed with BigDye Terminator
v3.1 (Applied Biosystems). Electrophoresis was performed on
anABI 3130Genetic Analyzer (Applied Biosystems). Obtain-
ed sequences were analysed in comparison to the reference
sequence NM_004562.2.
In two duplication cases (Ex2_5dup and Ex2dup), basic
PCR and direct sequencing was unsuccessful; hence,
breakpoint sequences were obtained using the inverse PCR
method with Mph1103I (Fermentas) and BbvI (New England
Biolabs) restriction enzymes, respectively. Genomic DNA
was digested, purified and subsequently ligated with T4
DNA ligase (Fermentas). Purified circular DNA fragments
encompassing breakpoints were amplified using DreamTaq
DNA Polymerase (Thermo Scientific) and sequenced as de-
scribed previously. Breakpoints identified using this method
were then confirmed by sequencing of the native DNA using
newly designed sets of primers (all primer sequences and re-
action conditions are available upon request).
Breakpoint region sequence analysis
Sequenced breakpoints of identified rearrangements were sub-
jected to bioinformatics analyses. RepeatMasker (http://www.
repeatmasker.org), a program screening DNA sequences for
interspersed repeats and low-complexity regions, was used to
check for repetitive elements 100 bp upstream and down-
stream of the breakpoint. Sequence similarity (unrelated to
repetitive elements) between 5′ and 3′ breakpoint regions
was checked with the ClustalW2 alignment tool (http://
www.ebi.ac.uk/Tools/msa/clustalw2). palindrome software
(http://emboss.bioinformatics.nl/cgi-bin/emboss/palindrome)
search allowed the identification of potential secondary
structure-forming sequences around the breakpoint region.
Results
Identification of PARK2 rearrangements
From the cohort of 344 PD patients that was screened for the
PARK2 rearrangements, deletions and duplications
encompassing different exons were identified in eight sub-
jects. The PARK2 PD is characterised by a broad range of
clinical phenotypes, sometimes atypical signs, early-onset,
slower progression, good response to levodopa, often with
more severe dopa-induced complications. PARK2 mutations
carriers revealed clinical features similar to those described
earlier. Asymmetrical rest tremor was the dominant symptom
at onset. In one case, lower limbs dystonia was the predomi-
nant syndrome. Depression and anxiety was the dominant and
early symptom in three cases. Response to levodopa treatment
was very good for all of them (in one case, it was excellent).
Three patients had early fluctuations and dyskinesias
(Table 1).
The PARK2 gene rearrangements, five deletions and three
duplications, were identified among patients with both EO
and LO forms of PD (Fig. 1). Four patients diagnosed with
EOPD showed compound heterozygosity, being carriers of
one deletion/duplication and a point mutation. Biallelic state
of these mutations was confirmed by parental analysis when
possible (Table 1, Fig. 2). In one case (EOPD), we were able
to prove biallelic deletions only by the analysis of the pro-
band’s parents, as in MLPA they appeared as one continuous
deletion. In the remaining three cases (two LOPD and one
EOPD), only one heterozygous mutation was identified. De-
letions encompassed from one to four exons in the region
between the 3rd and 7th exons of the gene. Only one deletion
(Ex4_7del) was recurrent and identified in unrelated families
(Tables 1 and 2). Duplications in two cases covered only one
exon (Ex2dup) and, in one case, four consecutive exons
(Ex2_5dup). Analysis of the data obtained from aCGH
allowed more detailed characterisation of the identified rear-
rangements in terms of their range and breakpoint localisation
(Table 2). Identification of the breakpoint regions enabled ex-
act mapping of the breakpoints and their analysis for sequence
features and similarity. Alignments of 5′ and 3′ sites of the
breakpoint regions did not show any long-range homologies
in any of the cases. Likewise, no repetitive DNA elements
were found on both sides of the breakpoints (100 bp upstream
and downstream; Table 2). The Ex4_7 deletion with identical
breakpoints was found in two probands. In the case of
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Ex2_5dup, the mutation was found to be in inverted orienta-
tion and contained a triplication of a small fragment of intron
1. Palindromic motifs in close proximity to the breakpoint
were found in six cases (seven alleles). The TTTAAA se-
quence, known for inducing curvature in the DNA, was found
in one case. In three cases, short insertions were identified,
although their origin is unknown. Subsequently, breakpoint
spanning sequences were aligned with normal ones, revealing
microhomologies being present at the breakpoint junctions in
six cases (7 out of 9 alleles) (Fig. 3).
Several papers have been published so far where exact
mutational breakpoints are mapped, but their characteristics
on the level of the DNA sequence are rarely discussed. We
decided to compare our findings to the data from two recently
published articles: Elfferich et al. (2011) and Mitsui et al.
(2010). Elfferich et al. submitted PARK2 breakpoints identi-
fied in 13 indexed PD patients (11 deletions and two duplica-
tions). Only one of the identified mutations (Ex4del) shared
identical breakpoint coordinates with previously reported ones
(Table 3). Based on the published coordinates of deletions/
duplications identified in that study, we were able to perform
sequence analysis of the 5′ and 3′ breakpoint regions for those
PARK2 rearrangements, and found that, in 9 of 13 cases,
microhomologies at breakpoint junctions were present
(Table 3). Moreover, one of the rearrangements, Ex2dup,
had exactly the same breakpoint coordinates as a duplication
published in the present study (ID8). Mitsui et al. also pub-
lished breakpoint analyses of rearrangements identified in a
large number of probands of both Asian and European de-
scent. Since we did not find coinciding breakpoints between
these two groups, only cases of European descent were taken
into consideration. We found that an identical Ex2dup muta-
tion, identified in Elfferich et al. and in the present study, was
also identified by Mitsui et al. Similarly, the majority of cases
reported by them contained microhomologies at breakpoint
junctions. In addition, a great majority of the rearrangements





PARK2 mutations Genotype (cDNA )a Main clinical symptoms PD type
Mutation1 Mutation2
1 32 39 Ex3del c.1337G>T
p.Cys446Phe
c.[172-?_412+?del];[1337G>T] Rigidity, depression and anxiety EOPD
2 31 40 Ex4_7del c.101_102del
p.Gln34Argfs*5
c.[413-?_871+?del(;)101_102del)] Rest tremor EOPD
3 26 29 Ex3del Ex4_7del c.[172-?_412+?del];[ 413-?_871+?del] Bradykinesia, depression and anxiety EOPD
4 24 33 Ex3_4del c.101_102del
p.Gln34Argfs*5
c.[174-?_534+?del];[101_102del] Dominating lower limbs dystonia EOPD
5 60 75 Ex6_7del – c.[619-?_871+?del];[=] Rest tremor, late fluctuation and
dyskinesia
LOPD
6 33 42 Ex2_5dup c.734A>T
p.Lys211Asn




7 36 61 Ex2dup – c.[8-?_171+?dup];[=] Rigidity, early fluctuation and
dyskinesia
EOPD
8 54 49 Ex2dup – c.[8-?_171+?dup];[=] Rest tremor, early fluctuation and
dyskinesia, excellent response for
levodopa treatment
LOPD
aHGVS v2 nomenclature, den Dunnen and Antonarakis (2000); reference sequence NM_004562.2 (NCBI37/hg19)
Fig. 1 Representation of the ranges of all PARK2 rearrangements found
in the study. Exons of the PARK2 gene are represented by numbered
boxes. Identified deletions are depicted in black and duplications in
grey. Rearrangements encompassed from one to four exons in the
region between exons 2 and 7. Mutations Ex4_7del and Ex2dup were
identified in two subjects
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identified in both of the mentioned studies fell into the region
between the 2nd and 8th exons of the PARK2 gene (Table 3).
Discussion
Since the gene’s discovery in 1998, a broad range ofmutations
in PARK2 has been identified. Abnormalities have been found
in all 12 exons of the gene, although a majority of them fall
into the region between exons 2 and 8 (Denison et al. 2003c).
Around 50% of the mutations are large rearrangements of one
or more exons (Hedrich et al. 2004), which, in heterozygous
configuration, are undetectable by traditional Sanger sequenc-
ing. In our study, we have identified large rearrangements in 8
of the 344 PD patients examined (2.33 % of patients, 1.31 %
of alleles). Identified rearrangements span the regions between
exons 2 and 8, which is in accordance with the fragility centre
of the FRA6E. However, most of the mutations were unique,
without common breakpoints. Only in two cases, with
Ex4_7del, were the breakpoints identical. These two subjects
are unrelated, to our knowledge. However, the kinship could
not be completely excluded, meaning that there may be a
common founder for this mutation, especially that no common
recombination susceptibility has been found in this region.
Based on case ID3, showing the continuous deletion of
exons from 3 to 7 in the MLPA analysis, we conclude that,
in terms of molecular diagnostics, it is important not to rely
exclusively on this method when identifying genomic rear-
rangements (Table 2). MLPA is convenient and robust to si-
multaneously screen many genomic samples, but in some in-
stances, significant information on the biallelic nature of the
mutation might be missed using only this technique. There-
fore, it is always necessary to check the parental state of iden-
tified mutation(s), if possible. Alternatively, more precise
techniques, like aCGH or specific PCR (Elfferich et al.
2011), may be used.
In some cases, of not only idiopathic but also EOPD, only
one heterozygous mutation is identified in PARK2 or other
AR-PD-associated genes (cases ID5, ID7 and ID8, Table 1),
which is difficult to interpret. However, it is possible that the
secondmutation is localised in one of the regulatory elements,
like promoters, enhancers or regulatory non-coding RNAs,
which is still beyond our detection capabilities. On the other
hand, it is plausible that heterozygousmutations in one of such
genes, juxtaposed with some other genetic variants, are suffi-
cient to cause the incidence of a disease or increase the risk of
its occurrence.
Genomic rearrangements may be brought about by various
mechanisms. The most common cause of genomic
Fig. 2 Four early-onset
Parkinson’s disease (EOPD)
pedigrees showing the PARK2
mutations’ inheritance in families.
Solid symbols individuals with
EOPD; open symbols unaffected
individuals without identified
mutations, mutations carriers on
one or, like in case 6 III-2, on both
alleles in the presymptomatic
stage at the moment of analysis;
index patients are denoted by
arrows






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































456 J Appl Genetics (2015) 56:451–461
Fig. 3 DNA sequences spanning eight identified rearrangements aligned
with corresponding normal intronic regions. Homology regions across
junctions are bold and underlined. The grey boxes indicate inserted
sequences. The arrows indicate palindromic sequences able to form
DNA hairpins and the asterisks indicate TTTAAA sequence known to
be able to induce a curvature in the DNA molecule. 1–3-bp
microhomologies were found in 6/8 cases. In the case of subject ID3,
both heterozygous deletions (Ex4-7del and Ex3del) are presented.
Breakpoints of the Ex4_7del mutation are identical in cases ID2 and
ID3. In the case of subject ID6, the duplication is represented by two
separate alignments (at the 5′ and 3′ sites) due to an inverted orientation.
In cases ID3, ID6 and ID8, the insertions are of unknown origin
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rearrangements are recombination events between two DNA
blocks of high homology, like low-copy repeats (LCRs),
LINE or SINE elements, via non-allelic homologous recom-
bination (NAHR) (Stankiewicz and Lupski 2002). NAHR
generates recurrent rearrangements, that can be observed in
the same shape in unrelated individuals, and may occur during
both mitosis and meiosis (Lam and Jeffreys 2006; Darai-
Ramqvist et al. 2008). However, despite the high density of
various repetitive elements in the intronic sequences of the
PARK2 gene in general, the breakpoint regions identified did
not contain homologous sequences upstream and downstream
of the breakpoint in any of cases. It means that recombination
events are not likely to have been responsible for generating
identified rearrangements. Non-recurrent rearrangements may
be driven by more than just one mechanism. Two of the most
prevalent mechanisms that may generate large rearrangements
a r e non -homo logou s end j o i n i ng (NHEJ ) and
microhomology-mediated break-induced replication
(MMBIR).
NHEJ is a major cellular mechanism for double-strand
break (DSB) repair (Moore and Haber 1996). Upon DSB,
NHEJ reconnects chromosome ends, very often editing them
before ligation, thus leaving so-called an information scar
(Lieber 2008). While editing NHEJ is able to add random
nucleotides at the site of a breakage to facilitate the strands’
alignment, which often occurs based on short homologies, and
ligation (Labhart 1999), NHEJ in most instances causes dele-
tions, but, in combination with homologous recombination
(HR), may also be responsible for duplications (Woodward
et al. 2005).
Another mechanism proposed to trigger non-recurrent ge-
nomic rearrangements is fork stalling and template switching
(FoSTeS), a mechanism that was originally proposed to ex-
plain multiple duplications found in Pelizaeus–Merzbacher
Table 3 Summary of breakpoint
characteristics of the
rearrangements identified in the










Ex1del – + (ATCT) 1 Elfferich et al. (2011)
Ex2delA – + (AG) 1 Elfferich et al. (2011)
Ex2delB – + (CCTGA) 1 Elfferich et al. (2011)
Ex2delC – + (T) 1 Elfferich et al. (2011)
Ex3del – – 1 Present study
Ex3del – + (TA) 1 Present study
Ex3delA – + (T) 1 Elfferich et al. (2011)
Ex3delB – + (CT) 2 Elfferich et al. (2011)
Ex3del – + (CT) 2 Mitsui et al. (2010)
Ex3_4del – + (T) 1 Present study
Ex3_5del – – 1 Elfferich et al. (2011)
Ex3_6del – + (GAT) 2 Mitsui et al. (2010)
Ex4del – – 2 Elfferich et al. (2011)a
Ex4del – + (AGCAC) 3 Mitsui et al. (2010)
Ex4_7del – + (TT) 2 Present study
Ex5del – + (T) 1 Elfferich et al. (2011)
Ex5_6del – + (CC) 3 Elfferich et al. (2011)
Ex6_7del – + (CT) 1 Present study
Ex8_10del – – 1 Elfferich et al. (2011)
PARK2 duplications
Ex2dup – + (TTA) 1 Present study
Ex2dup – – 4 Present study, Elfferich et al.
(2011), Mitsui et al. (2010)
Ex2_5dup+inv – + (T)/+ (CC) 1 Present study
Ex7dup SINE/Alu/ SINE/Alu – 4 Elfferich et al. (2011)
*FromMitsui et al. (2010); only cases with exon-spanning rearrangements of European descent were taken into
consideration
a Two cases also previously published by Hedrich et al. (2004)
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disease patients, and that has been later generalised as
MMBIR (Lee et al. 2007; Zhang et al. 2009). FoSTeS/
MMBIR is a microhomology-based mechanism that can ex-
plain very complex rearrangements, both deletions and dupli-
cations. It utilises microhomologies to switch the template
upon replication fork stalling and collapse. Replication con-
tinues based on a wrong template until the original fork is
restored. The template being switched to is usually in physical
proximity but not necessarily in close linear proximity to the
original replication fork. Such template switching may occur
several times before the replication process gets back to its
original template, resulting in complex rearrangements (Lee
et al. 2007).
As no extended homologies or repetitive elements were
found within the sequences encompassing the breakpoints
(Table 2), the occurrence of homologous recombination-
based mechanisms can be excluded. Alignments of the
breakpoint regions identified in our study with normal geno-
mic sequences reveal that 7 out of 9 breakpoint junctions
contain 1–3-bp homologies (Fig. 3). Most of the breakpoint
regions identified contained palindromic sequences which,
upon the spontaneous formation of stable secondary DNA
structure, may lead to replication fork stalling or cause a
DSB. Only one breakpoint region contains the TTTAAA se-
quence, known to be able to induce a curvature in the DNA
molecule (Trifonov 1985). Both palindromic and TTTAAA
motifs are potentially involved in DSB events. These findings
strongly support microhomology-mediated mechanisms fol-
lowing replication fork collapses, predominantly NHEJ and
FoSTeS/MMBIR, as major mechanisms responsible for geno-
mic rearrangements within the PARK2 gene, the fragility cen-
tre of FRA6E. An illustration of the FoSTeS/MMBIR rear-
rangement mechanism, based on the case ID6, is shown in
Fig. 4. Additionally, analysis of sequences around breakpoints
published in previous studies, where the majority of identified
PARK2 rearrangements also contained microhomologies at
the junctions, supports our hypothesis (Table 3).
The data on PARK2 rearrangements have been published
previously (Hedrich et al. 2004; Clarimon et al. 2005; Nakaso
et al. 2006; Bayrakli et al. 2007; Mitsui et al. 2010; Elfferich
et al. 2011). Our findings stay in concordance with these re-
ports; the majority of rearrangements identified in the PARK2
gene fall into the region between exons 2 and 8 (Tables 2 and
3).
The remaining question is why the FRA6E locus, as well as
other CFSs in the human genome, is so vulnerable to chromo-
somal breakages. Studies on PARK2 mutations reveal that, in
spite of the abundance of repetitive elements within the gene
sequence, homologous recombination is not a frequent mech-
anism generating rearrangements. Thus, the direct cause must
be rooted in other features of the sequence that delay the
replication processes by hindering replication forks’ progress
Fig. 4 Predicted fork stalling and template switching (FoSTeS)/
microhomology-mediated break-induced replication (MMBIR) mecha-
nism of the Ex2-5dup mutation in subject ID6. Upon replicating, the first
exon of the PARK2 gene replication fork stalled and one strand invaded
either the sister molecule or the homologue chromosome in inverted
orientation (1), resulting in inverted duplication. Subsequently, the orig-
inal forks were restored, but primed upstream of the point where it first
stalled (2), resulting in triplication of the grey-highlighted region
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and make themmore likely to collapse. It seems reasonable to
assume that the presence of palindromic sequences alone is
not responsible for this vulnerability, as such sequences are
found in many other regions of the genome. However, they
may be a facilitating factor for delaying the replication. First
studies to address the question of CFSs instability suggested
that late-replicating regions confer the susceptibility to rear-
rangements (Laird et al. 1987; Durkin and Glover 2007).
However, CFSs are not the only regions of the human genome
that undergo late replication. Recently, it has been found that
breakages occur preferentially at the transition zones between
sequences undergoing late and early replication (El Achkar
et al. 2005; Palumbo et al. 2010). FRA6E contains two such
zones, one being located within the sequence of intron 8 of
PARK2. Nonetheless, whether this is the primary reason why
chromosomes break at CFSs is still to be elucidated.
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